Summary According to the recently published report ’GrowthDifferentiation Factor 8 - Pipeline Review, H1 2020’; Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 9 molecules.
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF?) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.
The report ’GrowthDifferentiation Factor 8 - Pipeline Review, H1 2020’ outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 3, 3 and 2 respectively.
Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Genetic Disorders, Hematological Disorders and Oncology which include indications Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Anemia, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Limb-Girdle Muscular Dystrophy, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis, Neuromuscular Disorders, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) and Thalassemia.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
- The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Metabotropic Glutamate Receptor 7 - Drugs In Development, 2022’; Metabotropic...
Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Drugs In Development, 2022, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape. Dyskinesia...
978 pages •
By Global Industry Analysts
• Feb 2022
Abstract: What`s New for 2022? -Global competitiveness and key competitor percentage market shares -Market presence across multiple geographies - Strong/Active/Niche/Trivial -Online interactive peer-to-peer collaborative bespoke updates -Access to our digital archives and MarketGlass...
Strong support: Growth in funding since the COVID-19 outbreak is expected to support performance in 2021-22 Abstract Domiciliary Care in the UK Companies operating in the Domiciliary Care industry provide intensive, at-home nursing care to patients. Residential nursing care activities...
The global workplace stress management market reached a value of US$ 9.26 Billion in 2021. Looking forward, the analyst expects the market to reach a value of US$ 15.19 Billion by 2027 exhibiting a CAGR of 8.20% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as...
175 pages •
By The Business Research Company
• Jun 2022
Major players in the narcotics scanner market are Astrophysics Inc, Bruker Corporation, Thermo Fisher Scientific Inc, KLIPPER Enterprises, NUCTECH Company Ltd, OSI Systems Inc, Smiths Group Plc, Leidos, Viken Detection, Autoclear, Kapri Corp, CDex Inc, TactiScan, DetectaChem, and Rapiscan Systems. The global narcotics scanner market...
Brain Health Supplements Market Size, Share & Trends Analysis Report By Product (Natural Molecules, Herbal Extract), By Application, By Region, And Segment Forecasts, 2022 - 2030 Brain Health Supplements Market Growth & Trends The global brain health supplements market size is expected to...
The Global Mental Health Apps Market size is expected to reach $10.2 billion by 2027, rising at a market growth of 16.3% CAGR during the forecast period. Apps for mental health are tools that can be used on a smartphone or other mobile device. These apps are designed to help users become more self-aware by allowing them to control their...
The report considers the present scenario of the global mental wellness market and its market dynamics for 2022?2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent...
332 pages •
By Future Market Insight Global & Consulting Pvt Ltd
• Mar 2022
A recent market study published on the market offers global industry analysis for 2014-2021 & opportunity assessment for 2022–2032. The study offers a comprehensive assessment of the more important market dynamics. After conducting thorough research on the historical and current growth parameters of the CNS Treatment and Therapy Market,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.